Moxifloxacin, Inf/Oral
Quinolone · Quinolone
Indications
Acute exacerbation of chronic bronchitis, acute bacterial sinusitis, community acquired pneumonia (CAP) when other antibiotics cannot be used or have failed. Mild to moderate pelvic inflammatory disease, without associated tubo-ovarian or pelvic abscess, in combination with another antibiotic (unless moxifloxacin-resistant Neisseria gonorrhoea can be excluded). Completion of therapy in CAP and complicated skin and skin structure infections that have responded to IV moxifloxacin.
Dosage
ORAL: Adults: 400 mg daily. Treatment duration: Chronic bronchitis, 5-10 days; sinusitis, 7 days; pneumonia, 10 days; pelvic inflammatory disease, 14 days. Children: Not recommended. INJECTION: Adults: 400 mg by IV infusion over 60 min, once daily. Switch to oral treatment when clinically indicated. Total duration of treatment: Community acquired pneumonia: 7-14 days; Complicated skin and skin structure infections: 7-21 days. Children: Not recommended.
Administration
By IV infusion over 60 min once every 24 hour. No dilution of the inj is necessary. Compatibility: Stable in NS, D5W, D10W, LR. Stability: Store at 25°C. Do not refrigerate.
Adverse Effects
Abdominal pain, headache, dizziness, GI upset, QT prolongation in patients with hypokalaemia, abnormal LFTs. Superinfections, pseudomembranous colitis. Infusion: Also infusion site reactions.
Risk Factor (Pregnancy/Lactation)
Pregnancy: Contraindicated in pregnancy. Lactation: Contraindicated or not recommended. Contraindications: History of tendon disorders related to quinolone treatment, congenital or documented acquired QT prolongation, electrolyte disturbance, significant bradycardia, heart failure with reduced left ventricular ejection fraction, history of arrhythmia, liver impairment (Child Pugh C), LFTs >5 x ULN. MRSA. Precautions: Risk of seizures; discontinue if occur. Seek specialist ophthalmological advice if any effects on eyes. Risk of tendon inflammation/rupture; advise patients (especially elderly) to report limb pain or inflammation. Proarrhythmic conditions including acute MI and QT prolongation, discontinue immediately with signs of arrhythmia and perform ECG. Risk of pseudomembranous colitis; consider if patient has persistent diarrhoea. G6PD deficiency. Avoid excess UV exposure.…
Interactions
Drugs that prolong the QT interval including antiarrhythmics, antipsychotics, neuroleptics, TCADs, antimicrobials, antihistamines, cisapride. Corticosteroids, hypokalaemic agents, anticoagulants. Oral: Also, antacids, didanosine, sucralfate, charcoal, iron or zinc supplements.
Advice to Patient
Take with or without meals. Swallow whole tablet. Take medication atleast 4 hours before and 8 hours after aluminium or magnesium containing antacids, didanosine chewable buffered tablets or oral solution prepared from powder, multivitamins containing iron or zinc, or sucralfate. If a dose is missed, take it as soon as you remember, unless it is nearly time for the next dose. Contact prescriber if there is swelling of lips/tongue/mouth/throat, chest tightness or pain, palpitations, back pain, itching, difficulty in breathing, tendon pain, tendon inflammation, skin rash, tingling, dizziness, confusion, abnormal thinking, insomnia, anxiety, sunburn, changes in urinary pattern, vaginal itching/discharge/burning, changes in vision or hearing, unusual bleeding or bruising, blood in urine, severe persistent diarrhoea. Complete full course of therapy even if you feel better. Take sufficient…
Pharmacokinetics
Absorption: Well absorbed. Metabolism: Hepatic. Bioavailability: Approx. 90%. Half-life elimination: Single dose: Oral: 12-16 hrs. IV: 8-15 hrs. Excretion: Urine, faeces.
Brands with this active ingredient
Compiled by Healify Pharmacy from published drug references. How we compile it →
Always consult a pharmacist or doctor.